Last reviewed · How we verify
IP Lignocaine bolus and infusion
IP Lignocaine bolus and infusion is a Local anesthetic / Antiarrhythmic agent Small molecule drug developed by University of Auckland, New Zealand. It is currently FDA-approved for Local anesthesia, Ventricular arrhythmias (intravenous formulation).
Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local anesthesia, Ventricular arrhythmias (intravenous formulation).
At a glance
| Generic name | IP Lignocaine bolus and infusion |
|---|---|
| Sponsor | University of Auckland, New Zealand |
| Drug class | Local anesthetic / Antiarrhythmic agent |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Cardiology |
| Phase | FDA-approved |
Mechanism of action
Lignocaine works by reversibly binding to voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby inhibiting the influx of sodium ions. This prevents depolarization and blocks the generation and propagation of action potentials in sensory and motor nerves. When administered intravenously as a bolus or infusion, it can provide systemic analgesic and anti-arrhythmic effects in addition to local anesthetic properties.
Approved indications
- Local anesthesia
- Ventricular arrhythmias (intravenous formulation)
Common side effects
- Dizziness or lightheadedness
- Tremor or twitching
- Nausea
- Hypotension
- Bradycardia
- Seizures (at high doses)
Key clinical trials
- Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections (PHASE4)
- Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief (PHASE2, PHASE3)
- The Effect of Intravenous Lidocaine and Intraperitoneal Lidocaine Irrigation on Pain After Laparoscopic Cholecystectomy (PHASE4)
- Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IP Lignocaine bolus and infusion CI brief — competitive landscape report
- IP Lignocaine bolus and infusion updates RSS · CI watch RSS
- University of Auckland, New Zealand portfolio CI
Frequently asked questions about IP Lignocaine bolus and infusion
What is IP Lignocaine bolus and infusion?
How does IP Lignocaine bolus and infusion work?
What is IP Lignocaine bolus and infusion used for?
Who makes IP Lignocaine bolus and infusion?
What drug class is IP Lignocaine bolus and infusion in?
What development phase is IP Lignocaine bolus and infusion in?
What are the side effects of IP Lignocaine bolus and infusion?
What does IP Lignocaine bolus and infusion target?
Related
- Drug class: All Local anesthetic / Antiarrhythmic agent drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: University of Auckland, New Zealand — full pipeline
- Therapeutic area: All drugs in Anesthesia / Cardiology
- Indication: Drugs for Local anesthesia
- Indication: Drugs for Ventricular arrhythmias (intravenous formulation)
- Compare: IP Lignocaine bolus and infusion vs similar drugs
- Pricing: IP Lignocaine bolus and infusion cost, discount & access